Chemed Florida Quarterly ADC Targets After 2026 Admission Rebalancing

Analysis of Quarterly ADC Targets for Florida in 2026 After Admission Rebalancing

The excerpts provide qualitative and quantitative insight into the admission dynamics in Florida for VITAS, a hospice care provider under Chemed Corporation, for 2026 following the resolution of Medicare Cap issues and a strategic rebalancing of admissions.

---

Summary of Key Points Relevant to Florida ADC Targets:

1. Medicare Cap Resolution and Admission Mix Adjustment

   • By the end of January 2026, Chemed reported no billing limitation related to the Medicare Cap in their Florida combined program, a substantial improvement from prior years where the limitation was significant—$27.2 million in calendar 2025 down to none in 2026 for Florida alone ¹².
   • This resolution allowed management to begin refocusing admissions towards a more balanced mix between hospital-based admissions and other pre-admission sources.
   • The ideal long-term hospital admissions ratio is targeted between 42% and 45% of total admissions for sustainable patient base stability in Florida. At Q4 2025, hospital admissions reached 44.8%, within this preferred range signaling post-pandemic normalization ³⁴.

2. Impact on Average Daily Census (ADC) and Quarterly Cadence

   • The reimbursement and revenue dynamics from patient mix cause short-term ADC pressure and lower margins in the early part of 2026, since hospital admissions tend to yield shorter stays initially.
   • The management expects an ADC build-up over 2026 as more patients transition from short-stay to longer-stay status, improving revenue growth and EBITDA margins throughout the year, particularly in the second half of 2026 ³⁵.
   • Full year 2026 guidance expects 3.5% to 4% ADC growth across the VITAS business, which includes Florida, reflecting this progressive increase ².

3. New Market Expansion in Florida

   • In December 2025, the company received a Certificate of Need (CON) for Manatee County in Florida, adding a new territory that serves approximately 3,000 Medicare hospice patients annually.
   • This is part of a broader strategy of adding new territories in Florida (Pinellas, Marion, Pasco counties included) which have shown strong admissions within months of launch (40-50 first-time Medicare patients/month in Marion and Pasco, 28 in Pinellas in the second month) ³¹.

4. Financial Guidance and Quarterly ADC Target Implications

   • The company does not provide explicit quarterly ADC numeric targets for Florida exclusively, but does provide total VITAS ADC figures and growth rates.
   • Q4 2025 ADC was 22,462 patients across all geographies — a 1.3% increase from prior year — with Florida expected to grow faster given new CONs and improved cap status ².
   • CFO Mike Witzeman states that revenue and EBITDA in 2026 will be weighted 55% to the second half, implying ADC will likewise be lower in Q1/Q2 and accelerate in Q3/Q4 ²⁵.
   • The refocused admissions strategy signals that Q1 2026 ADC for Florida will be relatively muted due to elevated short-stay patients, but ADC growth will progressively ramp from Q2 onward.

---

Reasoned Quarterly ADC Targets for Florida in 2026 (Approximate)

• Baseline: VITAS ADC growth guided at 3.5–4% for full-year 2026.
• Admission Rebalancing Effect: Lower ADC in Q1 with ramp in Q2-Q4 due to mix shift (more balanced hospital/non-hospital admissions).
• Florida Market Growth Drivers: New territories with immediate monthly admissions of 28-50 first-time Medicare patients, strong stabilization post-cap, and strategic access to hospital admissions.

---

Additional Considerations

• The company emphasizes maintaining hospital admissions as 42-45% of Florida admissions to sustain long-term organic growth without revisiting Medicare Cap issues ³⁴.
• ADC growth in Florida is a key driver of revenue; hence, management’s focus on longer-stay patients to boost ADC—meaning that improved Florida ADC is expected to be a critical contributor to VITAS’s 5.5%-6.5% revenue growth guidance in 2026 ²⁵.
• The Manatee County market and other new CON markets in Florida (Pinellas, Marion, Pasco) together add incremental ADC volume that will partially ramp over the year, thus pushing ADC increases predominantly into H2 2026 ³¹.

---

Conclusion

• While exact quarterly hospital-specific ADC targets for Florida are not explicitly quantified in the filing, the data supports a gradual increase in average daily census over 2026, with a reset or slight decline in Q1 due to patient mix shifts and billing cycles, followed by progressive growth through Q2, Q3, and stronger in Q4.
• Chemed’s strategic admission rebalancing after resolving the Medicare Cap issue in Florida, coupled with geographic expansion via new CONs, supports confidence in mid-single-digit percentage ADC growth in Florida by the end of 2026, with most growth weighted to the latter half of the year.
• The primary target metric to watch is maintaining hospital admissions at about 42-45%, which underpins sustainable ADC increases without re-triggering cap liabilities.

---

This careful phasing of admissions enhancement combined with market expansion and stable cap positioning reflect a disciplined, capital-aware strategy consistent with Chemed’s conservative management style and historic performance. Investors should model Florida ADC with back-end weighted growth and a focus on admission mix stability to support sustainable long-term growth.

^3142567